Boston-based wearable technology company WHOOP has announced a $575 million Series G funding round, bringing its valuation to $10.1 billion. The round was led by Collaborative Fund, with participation from a broad group of institutional investors including Qatar Investment Authority, Mubadala Investment Company, Mayo Clinic and Macquarie Capital, alongside existing backers such as IVP and Foundry. Abbott joined as a strategic investor.
The round also included participation from prominent global athletes and individual investors, including Cristiano Ronaldo, LeBron James and Rory McIlroy, reflecting continued crossover between consumer health technology and professional sports.
WHOOP provides a wearable device that tracks key health metrics such as sleep, activity, heart health and menstrual cycles. Its platform delivers personalized insights designed to help users understand how daily behaviors influence long-term health and recovery needs. The company has also introduced a Blood Pressure Insights (BPI) feature, offering estimated systolic and diastolic readings.
Proceeds from the funding will support global expansion across Europe, Latin America, Asia and the Gulf Cooperation Council region. WHOOP also plans to scale its platform and invest in research and development, with more than 600 new roles expected to be added worldwide.
Cristiano Ronaldo, a WHOOP investor and global ambassador, said, "WHOOP has become one of the most important tools I use to support my long-term health. I am proud to participate in this round because I believe in the future we are building together. No other company has created a health platform this powerful that people are proud to wear."
The company’s growth follows a series of prior funding rounds, including a $200 million Series F in 2021 at a $3.6 billion valuation.
WHOOP is currently navigating regulatory scrutiny related to its BPI feature. In 2025, the U.S. Food and Drug Administration issued a warning letter stating the feature qualifies as a medical device requiring authorization. WHOOP has maintained that the feature is a wellness tool and should not fall under FDA regulation, citing precedents under the 21st Century Cures Act. The dispute remains ongoing.
Additionally, WHOOP has engaged in recent legal actions concerning intellectual property, including disputes with Shenzhen Lexqi Electronic Technology and Polar related to alleged product design similarities.
Click here for the original news story.